Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade D 115.25 -2.26% -2.66
ARGX closed down 2.26 percent on Friday, October 18, 2019, on 78 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ARGX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -2.26%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.26%
Narrow Range Bar Range Contraction -2.26%
Stochastic Reached Overbought Strength -2.26%
Weak + Overbought Other -2.26%
Gapped Up Strength -2.26%
Overbought Stochastic Strength -2.26%

Older signals for ARGX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Rheumatoid Arthritis Acute Myeloid Leukemia Myelodysplastic Syndrome Dyslipidemia Hematological Cancers Treatment Of Autoimmune Diseases Myasthenia Gravis Janus Kinase Inhibitor Tolerx Treatment Of Hematological Cancers
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 5 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 150.92
52 Week Low 71.48
Average Volume 153,287
200-Day Moving Average 125.9569
50-Day Moving Average 124.7474
20-Day Moving Average 113.755
10-Day Moving Average 112.433
Average True Range 3.3682
ADX 46.79
+DI 20.0549
-DI 33.929
Chandelier Exit (Long, 3 ATRs ) 117.9854
Chandelier Exit (Short, 3 ATRs ) 116.5946
Upper Bollinger Band 121.726
Lower Bollinger Band 105.784
Percent B (%b) 0.59
BandWidth 14.014329
MACD Line -2.8698
MACD Signal Line -4.18
MACD Histogram 1.3103
Fundamentals Value
Market Cap 3.1 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -90.75
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 121.66
Resistance 3 (R3) 121.81 119.83 120.59
Resistance 2 (R2) 119.83 118.20 119.75 120.23
Resistance 1 (R1) 117.54 117.19 116.55 117.39 119.88
Pivot Point 115.56 115.56 115.07 115.48 115.56
Support 1 (S1) 113.27 113.93 112.28 113.12 110.62
Support 2 (S2) 111.29 112.92 111.21 110.27
Support 3 (S3) 109.00 111.29 109.91
Support 4 (S4) 108.85